The progress of combined therapy of omalizumab and allergen immunotherapy in children with moderate to severe allergic asthma / 国际儿科学杂志
International Journal of Pediatrics
;
(6): 306-311, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-989086
ABSTRACT
Allergen immunotherapy(AIT)is considered the treatment capable of modifying the natural history of allergic respiratory disorders.The adverse reactions associated with AIT limit its clinical use in moderate to severe allergic asthma.Omalizumab is currently approved for the treatment of allergic asthma, chronic spontaneous urticaria, allergic rhinitis and other allergic diseases.A few trials have demonstrated the clinical efficacy of AIT and omalizumab combination therapy in children with moderate to severe allergic asthma.This review summarizes the research progress, mechanisma and application of omalizumab combined with AIT in children with moderate to severe allergic asthma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
International Journal of Pediatrics
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS